Low circulating pentraxin 3 levels in pregnancy is associated with gestational diabetes and increased apoB/apoA ratio: a 5-year follow-up study

Springer Science and Business Media LLC - 2016
Tove Lekva1,2, Annika Elisabeth Michelsen3,2, Jens Bollerslev4,3, Errol R. Norwitz1,5, Pål Aukrust6,3,2, Tore Henriksen7,3, Thor Ueland3,2
1Mother Infant Research Institute, Tufts Medical Center, Boston, USA
2Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
3Faculty of Medicine, University of Oslo, Oslo, Norway
4Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Oslo, Norway
5Department of Obstetrics & Gynecology, Tufts Medical Center and Tufts University School of Medicine, Boston, USA
6Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway
7Department of Obstetrics, Oslo University Hospital, Oslo, Norway

Tóm tắt

Gestational diabetes mellitus (GDM) is a significant risk factor for cardiovascular disease (CVD) in later life. Pentraxin 3 (PTX3) is an essential component of innate immunity and independently associated with the risk of developing vascular events. The aim of the study was to examine the relationships between GDM, cardiovascular risk, and plasma PTX3 in pregnancy and at 5 years after the index pregnancy. This population-based prospective cohort included 300 women who had an oral glucose tolerance test (OGTT) during pregnancy. Five years later, the OGTT was repeated along with dual-energy x-ray absorptiometry, lipid analysis, and pulse wave velocity analysis. Fasting PTX3 levels were measured four times during pregnancy and at follow-up. PTX3 levels were lower early in pregnancy and at 5 years follow-up in women who developed GDM. PTX3 levels throughout pregnancy were associated with body mass index. Low PTX3 levels in early pregnancy were predictive of an increased apoB/apoA ratio at 5-year follow-up. PTX3 at 5-year follow-up was inversely correlated with multiple metabolic risk factors for CVD, including body composition, arterial stiffness, dyslipidemia and previous GDM. Our results show that low plasma concentration of PTX3 in early pregnancy is associated with subsequent development of GDM and with an enhanced risk for CVD as estimated by an elevated apoB/apoA ratio at 5 years postpartum.

Từ khóa


Tài liệu tham khảo

Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8:639–49.

Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes mellitus. Obstet Gynecol Clin North Am. 2007;34:213–24.

Friis CM, Paasche Roland MC, Godang K, Ueland T, Tanbo T, Bollerslev J, et al. Adiposity-related inflammation: effects of pregnancy. Obesity (Silver Spring). 2013;21:E124–30.

Volpe L, Di CG, Lencioni C, Cuccuru I, Benzi L, Del PS. Gestational diabetes, inflammation, and late vascular disease. J Endocrinol Invest. 2007;30:873–9.

Gobl CS, Bozkurt L, Yarragudi R, Prikoszovich T, Tura A, Pacini G, et al. Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. Cardiovasc Diabetol. 2014;13:138.

Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm. 2013;2013:725102.

Salio M, Chimenti S, De AN, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055–64.

Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40.

Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699–708.

Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012;2012:657025.

Miyaki A, Maeda S, Choi Y, Akazawa N, Eto M, Tanaka K, et al. Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals. Am J Hypertens. 2013;26:1250–5.

Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471–7.

Zhou P, Luo X, Qi HB, Zong WJ, Zhang H, Liu DD, et al. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res. 2012;61:1005–12.

Castiglioni MT, Scavini M, Cavallin R, Pasi F, Rosa S, Sabbadini MG, et al. Elevation of plasma levels of the long pentraxin 3 precedes preeclampsia in pregnant patients with type 1 diabetes. Autoimmunity. 2009;42:296–8.

Todoric J, Handisurya A, Knapp B, Tura A, Pacini G, Kautzky-Willer A. Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. Eur J Clin Invest. 2013;43:341–9.

Yildirim M, Simavli SA, Uysal DA, Kaygusuz I, Uysal S. Is There Any Relationship between Plasma Pentraxin 3 Levels and Gestational Diabetes Mellitus? Gynecol Obstet Invest. 2015;80:223–7.

Roland MC, Friis CM, Voldner N, Godang K, Bollerslev J, Haugen G, et al. Fetal growth versus birthweight: the role of placenta versus other determinants. PLoS One. 2012;7:e39324.

Lekva T, Bollerslev J, Godang K, Roland MC, Friis CM, Voldner N, et al. beta-cell dysfunction in women with previous gestational diabetes is associated with visceral adipose tissue distribution. Eur J Endocrinol. 2015;173:63–70.

Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy–a review of the evidence. J Intern Med. 2006;259:493–519.

Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Leiva Sisnieguez CE, Leiva Sisnieguez BC, et al. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects. J Am Soc Hypertens. 2014;8:724–31.

Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014; 103:341–63.

Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.

Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring). 2008;16:1901–7.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995;26:485–90.

Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring). 2012;20:1313–8.

Olarescu NC, Jorgensen AP, Godang K, Jurik AG, Froslie KF, Bollerslev J. Dual-energy X-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone. J Clin Endocrinol Metab. 2014;99:E1727–31.

Ergun DL, Rothney MP. GE healthcare advancements in DXA body composition analysis: metabolic phenotyping with CoreScan. 2012. White paper.

Lekva T, Bollerslev J, Norwitz ER, Aukrust P, Henriksen T, Ueland T. Aortic stiffness and cardiovascular risk in women with previous gestational diabetes mellitus. PLoS One. 2015;10:e0136892.

Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–65.

Segovia SA, Vickers MH, Gray C, Reynolds CM. Maternal obesity, inflammation, and developmental programming. Biomed Res Int. 2014;2014:418975.

Larsson A, Palm M, Helmersson J, Axelsson O. Pentraxin 3 values during normal pregnancy. Inflammation. 2011;34:448–51.

Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care. 2007;30(Suppl 2):S246–50.

Gobl CS, Bozkurt L, Yarragudi R, Prikoszovich T, Tura A, Pacini G, et al. Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. Cardiovasc Diabetol. 2014;13:138.

Osorio-Conles O, Guitart M, Chacon MR, Maymo-Masip E, Moreno-Navarrete JM, Montori-Grau M, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011;301:E1254–61.

Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010;18:1871–4.

Miyaki A, Choi Y, Maeda S. Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice. Am J Med Sci. 2014;347:228–33.

Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003;33:465–73.

Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B, et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther. 2014;16:479.

Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005;25:1837–42.

Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2014;13:15.

Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.

Freire CM, Barbosa FB, de Almeida MC, Miranda PA, Barbosa MM, Nogueira AI, et al. Previous gestational diabetes is independently associated with increased carotid intima-media thickness, similarly to metabolic syndrome—a case control study. Cardiovasc Diabetol. 2012;11:59.

Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:925–31.

Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015;122:643–51.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả